Cat. No. 4875
Chemical Name: 4-[(2-Phenylethyl)amino]-6-quinazol
Biological ActivityCyclin-dependent kinase 8 (cdk8) inhibitor (IC50 = 280 nM). Also binds to cdk19 in an ATP-competitive manner. Inhibits p21-induced transcription. Reverses doxorubicin-induced tumor-promoting paracrine activities in vivo.
Licensing InformationSold under license from Senex Biotechnology.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Porter et al (2012) Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc.Natl.Acad.Sci.U.S.A. 109 13799. PMID: 22869755.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Senexin A from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Senexin A, supplier, cyclin, dependent, kinases, cdks, cdk8, cdk19, inhibits, inhibitors, p21, transcription, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitorEnzastaurin
Potent PKCβ inhibitorBMS 265246
Potent cdk1/2 inhibitorAutocamtide-2-related inhibitory peptide, myristoylated
CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptideMP A08
Selective ATP competitive SphK1 and 2 inhibitor; cell permeableAkti-1/2
Potent and selective dual Akt1 and 2 inhibitorVX 680
High affinity and selective Aurora kinase inhibitorImatinib mesylate
Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kitTGX 221
Potent and selective PI 3-kinase β inhibitorPF 543 hydrochloride
Potent and selective SphK1 inhibitor
December 3 - 7, 2016
San Francisco, CA,